"目錄號: HY-14538A
GPCR/G ProteinNeuronal Signaling-
Haloperidol hydrochloride 是有效的dopamine D2 receptor拮抗劑，為一種安定藥。
相關(guān)產(chǎn)品
Chlorpromazine hydrochloride-Brexpiprazole-Haloperidol-Cabergoline-Clozapine-Cariprazine hydrochloride-L-DOPA-Perphenazine-Dopamine hydrochloride-Oxidopamine hydrobromide-Sertindole-B-HT 920-Azaperone-Fluphenazine dihydrochloride-Iloperidone-
生物活性
Description
Haloperidol hydrochloride is a potentdopamine D2 receptorantagonist, widely used as an antipsychotic.
In Vivo
Haloperidol (1 mg) intra-arterially attenuates the dopamine-induced pancreatic secretion. Haloperidol (3 mg) completely inhibits the action of 10 μg of dopamine in the pancreas of the dogs[1]. Haloperidol (10 mg/kg) as well as chlorpromazine (CPZ, 15 mg/kg) blocks mescaline-induced altered behavior within 7 to 10 minutes when injected into the mice 45 minutes after 50 mg/kg (2 μc) of mescaline. Haloperidol has no effect on mescaline disappearance[2].
Clinical Trial
McMaster University
Postoperative Confusion
August 2013
Phase 3
Asan Medical Center-Seoul National University Hospital
Healthy
January 2008
Phase 1
University of Arkansas-Mount Sinai Hospital, Chicago
Agitation,Psychomotor-Haloperidol Causing Adverse Effects in Therapeutic Use-Lorazepam Causing Adverse Effects in Therapeutic Use-Loxapine Causing Adverse Effects in Therapeutic Use
August 15, 2017
Phase 4
Radboud University-ZonMw: The Netherlands Organisation for Health Research and Development
Delirium
June 2013
Phase 4
The University of Texas Health Science Center, Houston
Gastroparesis
November 2012
Phase 4
Minneapolis Medical Research Foundation
Agitation
April 2014
Phase 4
Harvard Medical School-National Institute of Mental Health (NIMH)-Dartmouth-Hitchcock Medical Center-Commonwealth Research Center, Massachusetts-Novartis
Schizophrenia
March 1996
Phase 4
Leiden University Medical Center-Dutch Diabetes Research Foundation
Insulin Resistance-Dyslipidemia
March 2005
Central Mental Clinic for Outpatients of Baku City
Schizophrenia
January 2005
Phase 4
Eric E. Prommer-Mayo Clinic
Nausea-Vomiting
March 2012
Early Phase 1
M.D. Anderson Cancer Center-National Institutes of Health (NIH)
Malignant Neoplasms of Independent (Primary) Multiple Sites
June 5, 2017
Phase 2-Phase 3
Khon Kaen University
Schizophrenia
June 2008
Queen's University
Cannabis Use Disorder
May 21, 2017
Phase 4
Shahid Beheshti University of Medical Sciences
Psychomotor Agitation
December 2012
Phase 3
National Taiwan University Hospital-Yu-Li Hospital
Schizophrenia-Schizoaffective Disorder-Agitation
July 2006
Phase 3
Chiang Mai University
Delirium
June 2009
Phase 3
OhioHealth
Headache, Migraine
February 2014
Phase 4
Northeastern University-National Institute on Aging (NIA)
Subsyndromal Delirium
September 2010
Phase 4
The Catholic University of Korea
Gynecological Disease
March 2012
Richard Hall-Dalhousie University-Nova Scotia Health Authority
Delirium-Agitation
June 2008
Zuyderland Medisch Centrum
Delirium
June 23, 2017
Phase 4
Austin Health-The Alfred
Delirium-Agitation-Ventilator Weaning-Respiration, Artificial-Intensive Care
January 2005
Phase 2
Eli Lilly and Company
Schizophrenia
July 2004
Phase 3
Catholic Health East
Agitation
November 2011
Oslo University Hospital
Psychosis-Schizophrenia
August 2010
Phase 4
Bronovo Hospital
Post-Operative Delirium-Hip Fracture
November 2005
Phase 3
Central South University-Wuhan Mental Health Institute-Capital Medical University-Shanghai Mental Health Center-Guangzhou Mental Hospital-Chongqing Mental Hospital
Schizophrenia
August 2008
Phase 4
New York State Psychiatric Institute-National Institute of Mental Health (NIMH)
Alzheimer's Disease-Psychosis-Agitation
January 1999
Phase 4
Janssen, LP
Schizophrenia-Schizoaffective Disorder
May 1996
Phase 4
Virginia Commonwealth University-National Cancer Institute (NCI)-American Cancer Society, Inc.
Healthy
November 2010
Centre hospitalier de l'Université de Montréal (CHUM)-Fondation des pompiers du Québec pour les grands br?lés
Delirium
February 2013
Phase 3
University of Colorado, Denver-Denver Health Medical Center
Delirium-Critical Illness
December 2005
Phase 2
VU University Medical Center
Delirium
November 2012
Phase 4
Tehran University of Medical Sciences
Ketamine Induced Agitation
July 2016
Phase 4
M.D. Anderson Cancer Center-National Cancer Institute (NCI)
Advanced Cancers
January 2014
Phase 2
Sandoz
Psychosis
April 1987
Phase 1
Mario Negri Institute for Pharmacological Research-Bristol-Myers Squibb
Schizophrenia
July 2007
Phase 4
UMC Utrecht
Delirium
February 2008
Phase 3
United States Naval Medical Center, Portsmouth
Migraine Headaches-Nausea-Restlessness
June 2013
Phase 4
University of Southern California-AstraZeneca
Agitation
May 2006
Phase 4
The University of Hong Kong-Queen Mary Hospital, Hong Kong-Tuen Mun Hospital-Pamela Youde Nethersole Eastern Hospital-Ruttonjee Hospital-Prince of Wales Hospital, Shatin, Hong Kong
Acute Agitation, Behavioural Emergency
December 2014
Phase 4
University of Pittsburgh-National Heart, Lung, and Blood Institute (NHLBI)
Delirium
March 2006
Phase 3
Duke University-Pfizer-National Institute of Mental Health and Neuro Sciences, India
Affective Disorders
April 2003
Phase 2-Phase 3
American University of Beirut Medical Center
Postoperative Nausea and Vomiting
September 2008
Phase 4
Peking University
Schizophrenia
May 2007
Western Michigan University School of Medicine
Headache-Migraine Disorders
October 2015
Phase 4
Shanghai Mental Health Center-Shanghai Hotmed Sciences Co.,LTD
Agitation
February 2009
Phase 2-Phase 3
Minneapolis Medical Research Foundation
Agitation,Psychomotor
June 15, 2017
